Lung squamous cell carcinoma

Slides:

Advertisements

Similar presentations

James R. Rigas Comprehensive Thoracic Oncology Program

Advertisements

I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=

I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=

1.DATABASE construction  n=1,715  Median OS=40.0 months, age: 64+/-10 yrs  Histology (adeno/squamous/large): 50% / 45% / 5%  Stage 1/2/3/4: 63% / 27%

LUNG CANCER Johns Hopkins Hospital Lung Cancer, Non-Small Cell , All Cases n=1364 Analytic - Initially Diagnosed and/or received all.

S L I D E 0 Elderly Patients Undergoing SBRT for Inoperable Early Stage NSCLC Achieve Similar Outcomes to Younger Patients Brandon R. Mancini, Henry S.

ESMO 2016 Nivolumab Data Study Ph Indication Line N Arms 1o EP ORR mDR

CPEB4 and IRF4 expression in peripheral mononuclear cells are potential prognostic factors for advanced lung cancer Yi-Ying Wu, Yi-Ting Hwang, Wann-Cherng.

ESMO 2016 Durvalumab Data Study / Abstract Ph Indication Line N Arms

Large cell undifferentiated carcinoma of lung

Overexpression of β-Catenin and Cyclin D1 is Associated with Poor Overall Survival in Patients with Stage IA–IIA Squamous Cell Lung Cancer Irrespective.

Compassionate People World Class Care

Prognosis of younger patients in non-small cell lung cancer

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Supporting Information for Meta-analysis

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

High Expression of PHGDH Predicts Poor Prognosis in Non–Small Cell Lung Cancer Jinhong Zhu, Jianqun Ma, Xudong Wang, Tianjiao Ma, Shu Zhang, Wei Wang,

WT G>A G>C G>T (n = 93) (n = 21) (n = 10) (n = 51)

Characterization of Aurora A and Its Impact on the Effect of Cisplatin-Based Chemotherapy in Patients with Non–Small Cell Lung Cancer Peng Kuang, Zuhua.

Frequency of JAK1 and JAK2 alterations and their association with overall survival in TCGA datasets. Frequency of JAK1 and JAK2 alterations and their association.

Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

Kaplan–Meier curves for a, b) progression-free survival (PFS) and c, d) overall survival (OS) in a, c) large-cell neuroendocrine carcinoma patients and.

Abstracts Journal of Thoracic Oncology

Prognostic signature of early lung adenocarcinoma based on the expression of ribonucleic acid metabolism–related genes Ruben Pio, PharmD, PhD, Jackeline.

MicroRNA Signature Predicts Survival and Relapse in Lung Cancer

David T. Cooke, MD, Danh V. Nguyen, PhD, Ying Yang, MS, Steven L

Factors predictive of prognosis after esophagectomy for squamous cell cancer Houhuai Li, MD, PhD, Qingzhen Zhang, Lin Xu, MD, Yijiang Chen, Yongxiang.

Patient-Reported Quality of Life After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer Frank J. Lagerwaard, MD, PhD, Neil K. Aaronson,

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Tumor histology predicts mediastinal nodal status and may be used to guide limited lymphadenectomy in patients with clinical stage I non–small cell lung.

Interstitial tumor-associated macrophages combined with tumor-derived colony- stimulating factor-1 and interleukin-6, a novel prognostic biomarker in non–small.

Lung Cancer and Prognosis in Taiwan: A Population-Based Cancer Registry Bing-Yen Wang, MD, Jing-Yang Huang, Ching-Yuan Cheng, MD, Ching-Hsiung Lin, MD,

Prognostic Impact of Preoperative Tumor Marker Levels and Lymphovascular Invasion in Pathological Stage I Adenocarcinoma and Squamous Cell Carcinoma of.

Impact of Lepidic Component Occupancy on Effects of Adjuvant Chemotherapy for Lung Adenocarcinoma Shinsuke Sasada, MD, PhD, Yoshihiro Miyata, MD, PhD,

Kaplan-Maier survival curves of 10-year DFS (A and B) and OS (C and D) according to PS 0 and PS≥1 in patients treated with adjuvant chemotherapy after.

Progression-Free Survival, Response Rate, and Disease Control Rate as Predictors of Overall Survival in Phase III Randomized Controlled Trials Evaluating.

A Pragmatic Approach to the Diagnosis of Nodal Micrometastases in Early Stage Non- small Cell Lung Cancer Esther Herpel, MD, Thomas Muley, PhD, Thomas.

Segmentectomy for selected cT1N0M0 non–small cell lung cancer: A prospective study at a single institute Hiroaki Nomori, PhD, Takeshi Mori, PhD, Koei.

High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer Heounjeong Go, MD, Yoon Kyung Jeon, MD, PhD, Hyo Jin.

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Brendon M. Stiles, MD, Mohamed K. Kamel, MD, Sebron W

Survival Differences by Gender for Resected Non-small Cell Lung Cancer: A Retrospective Analysis of 12,509 Cases in a Japanese Lung Cancer Registry Study

Prognostic Impact of Preoperative Tumor Marker Levels and Lymphovascular Invasion in Pathological Stage I Adenocarcinoma and Squamous Cell Carcinoma of.

High Expression of p300 Has an Unfavorable Impact on Survival in Resectable Esophageal Squamous Cell Carcinoma Yong Li, MD, Hao-Xian Yang, MD, Rong-Zhen.

Impact of Non–Small-Cell Lung Cancer-Not Otherwise Specified Immunophenotyping on Treatment Outcome Luisella Righi, MD, PhD, Tiziana Vavalà, MD, Ida.

Clinicopathologic Features and Computed Tomographic Findings of 52 Surgically Resected Adenosquamous Carcinomas of the Lung Yukio Watanabe, MD, Koji.

The Prognostic Impact of Cigarette Smoking on Patients with Non-small Cell Lung Cancer Ryo Maeda, MD, Junji Yoshida, MD, PhD, Genichiro Ishii, MD, PhD,

Prognostic value of bronchiolo-alveolar carcinoma component of small lung adenocarcinoma Masahiko Higashiyama, MD, Ken Kodama, MD, Hideoki Yokouchi,

Douglas E. Paull, MD, Glenda M. Updyke, PA-C, Michael A

Adjuvant Surgery after Carboplatin and VP16 in Resectable Small Cell Lung Cancer Giulia Veronesi, MD, Paolo Scanagatta, MD, Francesco Leo, MD, Tommaso.

Ernest Nadal, MD, Guoan Chen, MD, PhD, John R

Carcinoma of the esophagus: Prognostic significance of histologic type

Thymidylate Synthase Protein Expression by IHC and Gene Copy Number by SISH Correlate and Show Great Variability in Non–Small Cell Lung Cancer Murry.

Dissecting Pulmonary Large-Cell Carcinoma by Targeted Next Generation Sequencing of Several Cancer Genes Pushes Genotypic-Phenotypic Correlations to Emerge

Mediastinal lymph node dissection improves survival in patients with stages II and IIIa non-small cell lung cancer Steven M Keller, MD, Sudeshna Adak,

Figure S1. A. B. Figure S1. Kaplan-Meier curve of progression-free survival by treatment group in soluble heregulin (HRG)-high population (A) and soluble.

A Functional Polymorphism on Chromosome 15q25 Associated with Survival of Early Stage Non–Small-Cell Lung Cancer Guang Jin, MD, PhD, Eun Young Bae, BS,

MiR-520d-3p is an independent positive prognostic factor in ovarian cancer. miR-520d-3p is an independent positive prognostic factor in ovarian cancer.

A, PTEN loss signature score in resected SQCLC brain metastases.

Association between RB pathway alterations and poor prognosis in early-stage lung adenocarcinoma patients. Association between RB pathway alterations and.

MAPJD expression in lung cancers.

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Surgical resection of metachronous liver metastases

Influence of ASGR2 expression on survival.

lncRNA HOXA11-AS is overexpressed in gastric cancer tissues.

Time Trends of Surgical Outcome in Patients with Non-small Cell Lung Cancer Takeshi Hanagiri, MD, PhD, Tetsuro Baba, MD, PhD, Tetsuya So, MD, PhD, Manabu.

Fig. 1. FAM83H over-expression is associated with poor prognosis of CC

Video-Assisted Thoracoscopic Surgery Is a Safe and Effective Alternative to Thoracotomy for Anatomical Segmentectomy in Patients With Clinical Stage I.

Presentation transcript:

Lung squamous cell carcinoma Supporting data 4A Lung adenocarcinoma a b DFS OS P=0.914 HR=1.016 P=0.242 HR=1.189 Disease Free Survival (Proportion) Overall Survival (Proportion) Time (Year) Time (Year) Lung squamous cell carcinoma c DFS d OS P=0.879 HR=0.974 P=0.944 HR=1.010 Disease Free Survival (Proportion) Overall Survival (Proportion) Time (Year) Time (Year) Supporting data 4A. Survival analysis according to the MRS level from stage I-IV TCGA NSCLC data set. NSCLC cases of all stages were selected from lung adenocarcinoma and lung squamous cell carcinoma data set and DFS and OS was evaluated according to the MRS level. The expression of MRS was divided into two groups, upper 50% and lower 50%, based on the median value. P- value was obtained from Log-rank test.

Lung squamous cell carcinoma Supporting data 4B Lung adenocarcinoma a b DFS OS P=0.600 HR=0.916 P=0.657 HR=1.085 Disease Free Survival (Proportion) Overall Survival (Proportion) Time (Year) Time (Year) Lung squamous cell carcinoma c DFS d OS P=0.591 HR=0.895 P=0.525 HR=0.904 Disease Free Survival (Proportion) Overall Survival (Proportion) Time (Year) Time (Year) Supporting data 4B. Survival analysis according to the MRS level from stage I-II NSCLC data set of TCGA. NSCLC cases of stage I-II were selected from lung adenocarcinoma and lung squamous cell carcinoma data set and DFS and OS was evaluated according to the MRS level. The expression of MRS was divided into two groups, upper 50% and lower 50%, based on the median value. P- value was obtained from Log-rank test.

Lung squamous cell carcinoma Supporting data 4C Lung adenocarcinoma a b DFS OS P=0.063 HR=1.818 P=0.187 HR=1.408 Disease Free Survival (Proportion) Overall Survival (Proportion) Time (Year) Time (Year) Lung squamous cell carcinoma c DFS d OS P=0.702 HR=1.144 P=0.432 HR=1.255 Disease Free Survival (Proportion) Overall Survival (Proportion) Time (Year) Time (Year) Supporting data 4C. Survival analysis according to the MRS level from stage III-IV NSCLC data set of TCGA. NSCLC cases of stage III-IV were selected from lung adenocarcinoma and lung squamous cell carcinoma data set and DFS and OS was evaluated according to the MRS level. The expression of MRS was divided into two groups, upper 50% and lower 50%, based on the median value. P- value was obtained from Log-rank test.